title: Treatment of hypokalemic periodic paralysis with topiramate.
abstract: Hypokalemic periodic paralysis (hypoPP), the most common form of periodic paralysis, is a disorder characterized by attacks of transient muscle weakness associated with a drop in serum potassium level.The mainstay of treatment is potassium supplementation and drugs that inhibit the enzyme carbonic anhydrase. In this report we describe 11-year-old twins with hypoPP who were treated with topiramate, an anti-epileptic drug known to have carbonic anhydrase inhibitory properties. The patients experienced a decrease in the severity of their attacks upon initiation of treatment. Topiramate may warrant further investigation as a treatment option in hypoPP.
authors.affiliation: Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
authors.forename: Darren M
authors.initials: DM
authors.lastname: Fiore
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Strober
mesh_terms: D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D002256:Carbonic Anhydrases / Q000187:drug effects* / Q000502:physiology; D002648:Child; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D020514:Hypokalemic Periodic Paralysis / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D018908:Muscle Weakness / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects; D011191:Potassium Deficiency / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose; D002256:Carbonic Anhydrases